NCT03795272 (MaRuC) is a Phase 2 clinical trial of Rucaparib in Cervical Cancer, sponsored by Nordic Society of Gynaecological Oncology - Clinical Trials Unit.

Who is sponsoring NCT03795272?

NCT03795272 is sponsored by Nordic Society of Gynaecological Oncology - Clinical Trials Unit.

What drugs are being tested in NCT03795272?

Interventions in NCT03795272: Rucaparib, Placebo.

What condition does NCT03795272 study?

NCT03795272 studies Cervical Cancer.

Is NCT03795272 still recruiting?

NCT03795272 is currently withdrawn. Last updated 1 November 2019.

Last reviewed 2019-11-01 · How we verify

NCT03795272: MaRuC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rucaparib Maintenance Therapy in Advanced Cervical Cancer

Withdrawn Phase 2 Last updated 1 November 2019

What this trial tests

Phase 2 trial testing Rucaparib in Cervical Cancer. Withdrawn.

Timeline

1 October 2019

Primary endpoint
10 October 2019

10 October 2019

Quick facts

Lead sponsor	Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Start date	1 October 2019
Primary completion	10 October 2019
Estimated completion	10 October 2019
Sites	2 locations across Denmark

Drugs / interventions tested

Rucaparib (RUCAPARIB) — full drug profile →
Placebo

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Who can join

Adults 18 to 100, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy of PARP inhibitor, rucaparib as maintenance therapy for locally advanced cervical cancer

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
Wang Q, Peng H, Qi X, Wu M, et al · · 2020 · cited 114× · PMID 32728057 · DOI 10.1038/s41392-020-0199-6
Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications.
Toh M, Ngeow J. · · 2021 · cited 99× · PMID 34021944 · DOI 10.1002/onco.13829
Targeted Gene Delivery Therapies for Cervical Cancer.
Áyen Á, Jiménez Martínez Y, Boulaiz H. · · 2020 · cited 39× · PMID 32455616 · DOI 10.3390/cancers12051301
Drug repurposing as a potential source of innovative therapies in cervical cancer.
Capistrano I R, Paul S, Boere I, Pantziarka P, et al · · 2022 · cited 6× · PMID 36137575 · DOI 10.1136/ijgc-2022-003585
Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.
Montero-Macias R, Koual M, Crespel C, Le Frére-Belda MA, et al · · 2021 · cited 6× · PMID 33888155 · DOI 10.1186/s13256-021-02767-9

Verify or expand the search:

Other trials of Rucaparib

Trials testing the same drug.

NCT04676334 — CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib · Phase 3 · completed
NCT03462212 — Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, · Phase 1, PHASE2 · unknown
NCT04624178 — A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma · Phase 2 · active not recruiting
NCT04826198 — Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Pa · Phase 1, PHASE2 · terminated
NCT04539327 — Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study · completed

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Nordic Society of Gynaecological Oncology - Clinical Trials Unit trials

Trials by the same sponsor.

NCT05201001 — APX005M in Patients With Recurrent Ovarian Cancer · Phase 2 · withdrawn
NCT05142150 — Palliation in Gynae-oncology: Patients Expectations and Assessment of Care (PEACE) · recruiting
NCT05574673 — Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype · recruiting
NCT04742075 — Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer · Phase 2 · active not recruiting
NCT03267589 — Trial in Patients With Relapsed Ovarian Cancer · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03795272 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Last refreshed: 1 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03795272.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing